GHRP-6

GHRP-6 is a synthetic hexapeptide growth hormone secretagogue. Like GHRP-2, it acts on ghrelin receptors but is less selective and has more pronounced effects on appetite. It stimulates GH release but also increases appetite significantly due to its ghrelin-mimetic properties.

PubMed results: 632 · Human studies: 231 · Animal studies: 580

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

• Subcutaneous — standard range 100-300 mcg, 1-3 times daily

2-3 hours (moderate confidence)

• Growth hormone secretion via ghrelin receptor pathways (Strong preclinical): GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that stimulates GH release through ghrelin receptors; extensive preclinical and clinical research has documented acute GH secretory responses
• Appetite and orexigenic pathway research (Strong preclinical): Studies indicate GHRP-6 has pronounced ghrelin-mimetic effects on appetite, making it a research tool for orexigenic signaling in addition to GH release; appetite effects are generally more prominent than with more selective secretagogues such as GHRP-2
• GH axis probe and combination secretagogue research (Moderate clinical): Research literature has examined GHRP-6 alone and with GHRH analogs to study synergistic GH release patterns and pituitary responsiveness

• Marked appetite increase — Mild, Common. Clinical and research observations consistently report significant hunger and appetite stimulation due to GHRP-6's ghrelin-mimetic properties
• Cortisol and prolactin elevation — Mild, Common. GHRP-6 is less receptor-selective than some later secretagogues; research has associated it with measurable increases in cortisol and prolactin alongside GH release
• Water retention or flushing — Mild, Uncommon. GH secretagogue research has occasionally noted transient flushing, mild fluid retention, or injection-site reactions following administration

• Active malignancy or GH/IGF-1–sensitive neoplastic disease (Theoretical / Preclinical): Stimulation of GH release raises theoretical concern about supporting growth signaling in cancer-related research contexts; protocols typically exclude active malignancy
• Uncontrolled diabetes mellitus (Clinical): GH elevation and appetite stimulation can adversely affect glycemic control; clinical research frameworks often restrict poorly controlled metabolic disease

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water